论文部分内容阅读
目的观察重组人白细胞介素-11(rhIL-11)治疗化疗所致血小板(PLT)减少的疗效和不良反应。方法采用患者自身对照研究,对第1个周期化疗(对照组)后PLT≤70×109/L的42例实体瘤患者,第2个周期(治疗组)采用相同方案化疗,化疗结束后24h开始,皮下注射rhIL-Ⅱ25g/kg,1次/d,连用7～14d,或至PLT≥100×109/L时停药。结果治疗组化疗后各时点PLT计数均高于对照组。化疗后,治疗组和对照组PLT最低值分别为(105.2±51.5)×109/L、(54.6±45.5)×109/L,两组差异有统计学意义(P<0.01)。PLT恢复正常时间,治疗组为2～20d,对照组为5～28d,中位数分别为6、13d,两组差异有统计学意义(P<0.01)。rhIL-Ⅱ的不良反应主要包括:乏力、关节肌肉酸痛、头痛、心悸、水肿和发热等,大多较轻,可以耐受。结论rhIL-11能刺激血小板增生,治疗化疗引起得血小板降低,是一种有效、安全的药物,值得进一步研究。
Objective To observe the efficacy and adverse reactions of recombinant human interleukin-11 (rhIL-11) in the treatment of chemotherapy-induced reduction of platelet (PLT). Methods 42 patients with solid tumors with PLT ≤70 × 109 / L after the first cycle of chemotherapy (control group) were treated with the same regimen in the second cycle (treatment group) after 24 hours after the end of chemotherapy , Subcutaneous injection of rhIL-Ⅱ25g / kg, 1 time / d, once every 7 ~ 14d, or until the PLT≥100 × 109 / L withdrawal. Results After treatment, the PLT count of the treatment group was higher than that of the control group. After chemotherapy, the lowest values of PLT in treatment group and control group were (105.2 ± 51.5) × 109 / L and (54.6 ± 45.5) × 109 / L respectively, with significant difference between the two groups (P <0.01). PLT returned to normal, the treatment group was 2 ~ 20d, the control group was 5 ~ 28d, the median was 6,13d, the difference between the two groups was statistically significant (P <0.01). Adverse reactions to rhIL-II include: fatigue, joint soreness, headache, palpitations, edema and fever, mostly light and tolerable. Conclusion rhIL-11 can stimulate platelet hyperplasia and reduce platelet induced by chemotherapy. It is an effective and safe drug and deserves further study.